Introduction {#S1}
============

The cerebellum (CB) has dense anatomical and functional connections with sensorimotor cortex ([@B1]--[@B3]). Functional perturbation in these connections may underlie pathophysiology of several movement disorders, such as Parkinson's disease (PD), dystonia, and spinocerebellar ataxia ([@B4]--[@B6]). Recently, non-invasive brain stimulation (NBS) has been extensively used as a tool in studying the CB--M1 interactions \[for a review, see Tremblay et al. ([@B7])\]. For instance, the physiological cerebellar inhibition (CBI) to M1 is currently tested by paired transcranial magnetic stimulation (TMS) of the CB and the contralateral M1 ([@B8]). Theta burst stimulation, a type of patterned repetitive transcranial magnetic stimulation (rTMS) ([@B9]), of the lateral CB is able to modulate the excitability of the contralateral primary motor cortex (M1) in healthy subjects ([@B10]). Paired associative stimulation (PAS) and transcranial direct current stimulation (tDCS) are another two types of NBS. The classic PAS protocol consists of repetitive TMS pairing with median nerve electric stimulation ([@B11]). Evidence has shown that simultaneous CB tDCS may abolish the M1 motor plasticity induced by PAS ([@B12]). In term of the M1 motor plasticity modulated by the cerebellar afferent information, our previous work has shown that a paired corticocortical TMS protocol targeting the CB and the contralateral M1 can change the M1 excitability by following the spike-timing dependent principle in young healthy subjects ([@B13]). Such kind of modulation of M1 plasticity is supposed to depend on a functionally normal cerebello--dentato--thalamo--cortical (CDTC) pathway.

Parkinson's disease is a common movement disorder, in principle involving the basal ganglia pathology. However, the CDTC pathway may also play an important role on the pathogenesis of parkinsonian tremor ([@B4], [@B14]). Spinocerebellar ataxia type 3 (SCA3) has a primary degeneration of the cerebellar nuclei and a wide spreading dysfunction among CB, brainstem, and basal ganglia ([@B5], [@B15], [@B16]). This study aims to investigate whether M1 motor plasticity is inducible through the paired associative TMS on the CB and the contralateral M1 for the healthy aged subjects, patients with PD and SCA3. We hypothesized that neurodegenerative disorders involving the CDTC circuit may hamper this kind of M1 plasticity.

Materials and Methods {#S2}
=====================

Subjects {#S2-1}
--------

In total, 29 right-handed ([@B17]) subjects were recruited in this study. All of the 10 PD patients (age, 69.1 ± 9.9 years; three females) fulfilled the UK Brain Bank diagnostic criteria ([@B18]). There were nine gene-confirmed SCA3 patients (age, 49.7 ± 15.9 years; six females) (Table [1](#T1){ref-type="table"}). All patients were requested to discontinue medications for at least 24 h prior to the two sessions of experiments. Ten healthy subjects were recruited as the control group (age, 65.2 ± 14.3 years; four females). All participants gave their written informed consent before joining the study. They all received a routine brain MRI examination to exclude focal structure lesion. The experimental procedures were in accordance with the latest revision of the Declaration of Helsinki. Approval by the local ethics committee of the China Medical University Hospital was obtained (CMUH103-REC1-015).

###### 

Demographic and clinical characteristics of the Parkinson's disease (PD) and spinocerebellar ataxia type 3 (SCA3) patients.

  PD group (No.)         Age (years)       Sex       Disease duration (years)       Motor/total UPDRS (more affected side)                                               Hoehn and Yahr stage             Medication (daily dose in mg) (LED)
  ---------------------- ----------------- --------- ------------------------------ ------------------------------------------------------------------------------------ -------------------------------- ---------------------------------------------------------------------------
  1                      66                F         3                              38/55 (L)                                                                            2.5                              Levodopa 300 (300)
  2                      70                M         8                              48/64 (L)                                                                            3                                Levodopa 350, trihexyphenidyl 3, amantadine 300, rotigotine 4 (770)
  3                      67                F         7                              18/22 (L)                                                                            2                                Levodopa 300, biperiden 4, ropinirole PR 4 (380)
  4                      57                M         6                              27/33 (L)                                                                            2                                Levodopa 300, pramipexole 0.75, amantadine 300 (675)
  5                      79                F         5                              32/45 (L)                                                                            2.5                              Levodopa 100, amantadine 100, propranolol 20 (200)
  6                      82                M         5                              27/41 (R)                                                                            2.5                              Levodopa 300, entacapone 600, amantadine 100, propranolol 30 (499)
  7                      75                M         1                              16/31 (R)                                                                            2                                Levodopa 100 (100)
  8                      80                M         3                              24/30 (L)                                                                            2                                Levodopa 200 (200)
  9                      62                M         2                              28/40 (R)                                                                            2                                Levodopa 300, biperiden 3, ropinirole 0.75 (315)
  10                     53                M         3                              15/26 (R)                                                                            2                                Levodopa 200 (200)
                                                                                                                                                                                                          
  **SCA3 group (No.)**   **Age (years)**   **Sex**   **Disease duration (years)**   **Clinical rating scale for cerebellar function[^a^](#tfn1){ref-type="table-fn"}**   **Abnormal CAG repeat number**   **Medication (daily dose in mg) (LED)**
                                                                                                                                                                                                          
  1                      47                M         20                             13                                                                                   73                               Levodopa 100, amantadine 100, baclofen 20, piracetam 2,400 (200)
  2                      62                F         3                              11                                                                                   62                               Amantadine 150, biperiden 3 (150)
  3                      43                M         16                             21                                                                                   82                               Amantadine 300, trihexyphenidyl 4, tizanidine 9, flunarizine HCl 15 (300)
  4                      75                F         13                             24                                                                                   66                               Alprazolam 0.25 (0)
  5                      30                F         4                              12                                                                                   76                               Tizanidine 3, amantadine 300 (300)
  6                      59                F         10                             22                                                                                   71                               None (0)
  7                      62                M         2                              12                                                                                   66                               Piracetam 2,400 (0)
  8                      30                F         3                              12                                                                                   76                               Amantadine 150 (150)
  9                      39                F         3                              14                                                                                   74                               Levodopa 100, amantadine 100 (200)

*^a^The rating scale was developed by S. Massaquoi and M. Hallett. A higher score represents a more severe cerebellar dysfunction. The maximal score of the scale is 30 \[for a detail, see Wessel et al. ([@B19])\]*.

*F, female; L, left; LED, [l]{.smallcaps}-DOPA equivalent dose ([@B20]); M, male; R, right; UPDRS, unified PD rating scale*.

Procedures {#S2-2}
----------

### Measurement of Motor-Evoked Potential (MEP), Short-Interval Intracortical Inhibition (SICI), Intracortical Facilitation (ICF), and CBI {#S2-2-1}

Subjects were seated on a comfortable reclining chair with both arms relaxed. Cortical excitability of the hand representation of the left primary motor cortex (M1~HAND~) was tested with single-pulse and paired-pulse TMS in blocks of measurements immediately before CB → M1 PAS (baseline, B0) and immediately, 30 and 60 min after CB → M1 PAS (P1, P2, and P3, respectively). The target muscle for the electromyographic recordings was first dorsal interosseus (FDI) of the right hand. The individual resting motor threshold (RMT) and active motor threshold (AMT) were determined over the left M1~HAND~, and AMT was additionally determined over the inion (inion AMT) prior to the baseline recording. The detailed procedure for determining RMT and AMT has been described elsewhere ([@B13], [@B21]). SICI, ICF, and CBI were studied using the same paired-pulse TMS protocols as we reported before ([@B13]). A double cone coil (inner diameter of each wing, 110 mm; Magstim Co., UK) was used for the cerebellar stimulation. The interstimulus interval of the paired-pulse TMS for SICI, ICF, and CBI was 2, 10, and 6 ms, respectively. These intervals were determined based on the previous studies in which the most significant effect was usually obtained with these intervals ([@B8], [@B13], [@B22]--[@B24]). Due to limitation of the recording time for each session, we did not measure the other intervals in this study. Twenty trials of single MEPs were recorded at each time point (B0, P1, P2, and P3) with the intertrial interval varied ranging from 7.5 to 12.5 s. Monophasic TMS pulse was delivered for the single MEP recording. Twelve single-pulse and 12 paired-pulse TMS with a pseudorandomized order were measured at each time point for SICI, ICF, and CBI. The intertrial interval was ranging from 3.75 to 6.25 s to limit anticipation. Biphasic TMS pulse was used for the SICI, ICF, and CBI recording.

### CB → M1 PAS {#S2-2-2}

The inion AMT and the TMS intensity, which can evoke around 1 mV peak-to-peak amplitude of the MEP at right FDI muscle, were applied for the CB → M1 PAS. A subthreshold condition TMS pulse with 95% inion AMT was delivered over right CB by using a double cone coil and followed by a suprathreshold M1~HAND~ stimulus with a figure-of-eight coil. There were two intervals between the condition stimulus and the left M1~HAND~ stimulus. Based on the principle of spike-timing dependent plasticity (STDP) and our previous finding, the interval of 6 ms (CB → M1 PAS~6ms~) is supposed to induce LTD-like effect and the interval of 2 ms (CB → M1 PAS~2ms~) to induce LTP-like effect ([@B13]). A total of 120 condition-test TMS pairs with monophasic pulse were delivered at a frequency of 0.25 Hz (i.e., 8 min in duration of the CB → M1 PAS) in each of the two sessions. Every subject completed two sessions by a pseudorandomized order with an interval of at least 7 days in order to avoid interactions between the two sessions.

Statistical Analysis {#S2-3}
--------------------

Data distribution was first examined with Shapiro--Wilk testing (SPSS 16.0). Non-parametric Kruskal--Wallis *H* test and Mann--Whitney *U* test were used for violation of normal distribution. Conditional on a statistical significance of the Kruskal--Wallis *H* test for three-group comparison (*P* \< 0.05), *post hoc* analysis was conducted using Mann--Whitney *U* test with Bonferroni's correction for multiple comparisons. In case of normal distribution, repeated measures analyses of variance were applied to test the effects of CB → M1 PAS on MEP amplitude, SICI, ICF, and CBI. Data are reported as means ± SD if not stated otherwise.

Results {#S3}
=======

All of the subjects were cooperative throughout the experimental procedures. None of them reported any noticeable adverse effects during or after the study. The gender distribution was not significantly different between the groups (*P* \> 0.1 by Chi-squared test). The mean age of the SCA3 group (49.7 ± 15.9 years) was significantly less than the PD group (69.1 ± 9.9 years; *P* \< 0.05 by non-parametric Mann--Whitney *U* test). There were no differences for RMT, AMT, MEP~1mV~ of M1~HAND~, and inion AMT between groups (all *P* \> 0.5 by one-way ANOVA, Table [2](#T2){ref-type="table"}). The baseline SICI and CBI were significantly less in the SCA3 group (79.1 ± 41.1 and 101.9 ± 17.2%, respectively) than those in the healthy control (HC) group (45.9 ± 22.9 and 84.7 ± 15.1%, respectively) (*P* \< 0.05 by Mann--Whitney *U* test, Table [2](#T2){ref-type="table"}). The levodopa equivalent dose was higher in the PD group (363.9 ± 220.3 mg) compared to the SCA3 group (144.4 ± 121.0 mg) (*P* \< 0.05 by unpaired *t*-test).

###### 

Baseline parameters of transcranial magnetic stimulation (TMS) in the three groups.

         RMT (%MSO)    AMT (%MSO)   MEP~1mV~[^a^](#tfn2){ref-type="table-fn"} (%MSO)   Inion AMT (%MSO)   Conditional TMS intensity for SICI (%MSO)   Baseline SICI[^b^](#tfn3){ref-type="table-fn"}(%)   Conditional TMS intensity for ICF (%MSO)   Baseline ICF[^b^](#tfn3){ref-type="table-fn"} (%)   Conditional TMS intensity for CBI (%MSO)   Baseline CBI[^b^](#tfn3){ref-type="table-fn"} (%)
  ------ ------------- ------------ -------------------------------------------------- ------------------ ------------------------------------------- --------------------------------------------------- ------------------------------------------ --------------------------------------------------- ------------------------------------------ ---------------------------------------------------
  HC     51.6 ± 7.9    47.3 ± 8.1   67.0 ± 12.4                                        44.1 ± 4.5         40.0 ± 5.5                                  45.9 ± 22.9[^§^](#tfn4){ref-type="table-fn"}        40.0 ± 5.5                                 148.7 ± 32.7                                        41.9 ± 4.3                                 84.7 ± 15.1[^§^](#tfn4){ref-type="table-fn"}
  PD     48.6 ± 10.4   44.6 ± 9.3   65.1 ± 15.6                                        42.1 ± 4.5         40.2 ± 8.7                                  62.4 ± 30.7                                         39.7 ± 9.5                                 147.9 ± 41.2                                        40.0 ± 4.3                                 91.9 ± 21.6
  SCA3   50.9 ± 7.6    47.1 ± 7.2   61.1 ± 13.7                                        44.1 ± 5.1         42.3 ± 7.5                                  79.1 ± 41.1[^§^](#tfn4){ref-type="table-fn"}        42.3 ± 7.7                                 146.3 ± 62.7                                        41.9 ± 4.9                                 101.9 ± 17.2[^§^](#tfn4){ref-type="table-fn"}

*Data are presented as mean ± SD*.

*^a^The intensity of TMS producing motor-evoked potentials (MEPs) of on average 1 mV in peak-to-peak amplitude in the resting first dorsal interosseus*.

*^b^Data shown by the mean conditioned MEP amplitude as a percentage of the unconditioned mean*.

*^§^P \< 0.05 by non-parametric Mann--Whitney U test with Bonferroni's correction*.

*AMT, active motor threshold; CBI, cerebellar inhibition; HC, health control; ICF, intracortical facilitation; MSO, maximum stimulator output; PD, Parkinson's disease; RMT, resting motor threshold; SCA3, spinocerebellar ataxia type 3; SICI, short-interval intracortical inhibition*.

Since violation of normal distribution was found in parts of the MEP, SICI, ICF, and CBI datasets, non-parametric testing was applied to examine the effect of PAS Protocol (CB → M1 PAS~6ms~ vs. CB → M1 PAS~2ms~), Time (B0, P1, P2, and P3), and Group (HC, PD, and SCA3). Comparisons of MEP showed significant MEP facilitation at P1 by CB → M1 PAS~2ms~ and MEP depression at P1 and P2 by CB → M1 PAS~6ms~ for the HC group only (*P* \< 0.05 by Mann--Whitney *U* test, Figure [1](#F1){ref-type="fig"}). Compared to the HC group, a significant reduction of SICI in the SCA3 group was found irrespective of PAS protocols (*P* \< 0.05 by Mann--Whitney *U* test, Figure [2](#F2){ref-type="fig"}). There is a significant reduction of CBI at P1 and P3 compared to B0 in the HC group but not in the other two groups irrespective of PAS protocols (both *P* \< 0.05 by Mann--Whitney *U* test, Figure [3](#F3){ref-type="fig"}). The baseline CBI at B0 was significantly reduced in the SCA3 group compared to the HC group, as also shown in Table [2](#T2){ref-type="table"}. In addition, there was a significant difference of CBI at P3 between the HC group and the PD group (Figure [3](#F3){ref-type="fig"}). The difference was explained by the significant reduction of CBI at P3 in the HC group. There were no effects of PAS Protocol, Time, and Group on ICF (all *P* \> 0.05 by Mann--Whitney *U* test).

![**(A)** Motor-evoked potential (MEP) amplitudes (mean ± SEM in mV) recorded from the right first dorsal interosseus muscle in the healthy control (HC), Parkinson's disease (PD), and spinocerebellar ataxia 3 (SCA3) groups. Comparisons between pre- (B0), immediate (P1), 30 min (P2), and 60 min (P3) post-CB → M1 PAS~2ms~ vs. CB → M1 PAS~6ms~ were shown. A significant MEP facilitation at P1 after CB → M1 PAS~2ms~ and MEP suppression at P1 and P2 after CB → M1 PAS~6ms~ were noted for the HC group (\**P* \< 0.05 by non-parametric Mann--Whitney *U* test with Bonferroni's correction). **(B)** The averaged MEP waveforms for the 10 subjects in the HC group. **(C)** Individual MEP data of the HC group (*n* = 10).](fneur-08-00445-g001){#F1}

![Mean short-interval intracortical inhibition (SICI) \[given as percentage of the conditioned motor-evoked potential (MEP)/unconditioned MEP\] in the three groups. Note that the spinocerebellar ataxia type 3 (SCA3) group showed a significant reduction of SICI compared to the healthy control (HC) group (\**P* \< 0.05 by non-parametric Mann--Whitney *U* test).](fneur-08-00445-g002){#F2}

![Mean cerebellar inhibition (CBI) \[given as percentage of the conditioned motor-evoked potential (MEP)/unconditioned MEP\] in the three groups. In the healthy control (HC) group, there was a significant reduction of CBI at P1 and P3 compared to B0 (\**P* \< 0.05 by non-parametric Mann--Whitney *U* test). The spinocerebellar ataxia type 3 (SCA3) group showed a significant reduction of the mean CBI compared with the HC group at B0 (^\#^*P* \< 0.05 by non-parametric Mann--Whitney *U* test). Compared to the PD group, the HC group showed a significant reduction of the mean CBI at P3 (^\#^*P* \< 0.05 by non-parametric Mann--Whitney *U* test).](fneur-08-00445-g003){#F3}

Discussion {#S4}
==========

CB → M1 PAS-Induced Corticospinal Excitability {#S4-1}
----------------------------------------------

The current data revealed that aged subjects have a similar STDP-like M1 motor plasticity induced by CB → M1 PAS as young subjects. Despite aging may decrease the conventional PAS-induced LTP-like plasticity and increase variability ([@B25]--[@B27]), it might not significantly affect the MEP responses of the CB → M1 PAS. The fact renders a possibility that age may have a distinct influence on different PAS protocols. More data are required to clarify this assumption.

The current data on PD patients are consistent with the findings investigated by conventional PAS. Accumulated evidences have shown that PD patients have a deficit of motor cortical plasticity on their off-medication condition ([@B28], [@B29]). Nevertheless, whether the lack of CB → M1 induced M1 plasticity in our PD patients' results from M1 pathology or perturbation within the long CDTC pathway is difficult to determine by the current data. Previous TMS studies on tremor have suggested that the CDTC circuit may play a pivotal role in the pathogenesis of parkinsonian tremor ([@B4], [@B14]). Either focal M1 dysplasticity or functional perturbation of the CDTC circuit can disrupt the associative plasticity induced by the CB → M1 PAS.

Patients with cerebellar degeneration also show impaired M1 plasticity by the conventional PAS protocol ([@B30]). The conventional PAS provokes STDP-like M1 plasticity through the somatosensory pathway where it has complex connections to the CB. A possible explanation is that M1 plasticity is influenced by the defect of the capability of cerebellar processing of time-specific sensory volleys in these patients ([@B30]). The CB → M1 PAS provides a direct route to evaluate whether cerebellar pathology affects the associative plasticity in M1. In this study, we investigated the patients with a homogenous genotype. Findings support the notion that either CB *per se* or its efferent pathways could play a role in M1 motor plasticity.

SICI/ICF Response {#S4-2}
-----------------

It has been found that the conventional PAS protocol does not alter SICI ([@B11]). The effect of the conventional PAS depends on directly antidromic volleys from S1 to M1 neurons where fast-spiking inhibitory interneurons, thought as SICI mediators ([@B31], [@B32]), may not be actively engaged in. Nevertheless, repetitive TMS on CB likely shapes M1 activities through an interaction between these inhibitory interneurons and pyramidal cells ([@B33]). The animal study has shown that STDP protocols always result in LTD at synapses between the inhibitory interneurons and pyramidal cells ([@B34]). Different from the previous finding showing a non-specific decrease in SICI following CB → M1 PAS protocols ([@B13]), SICI was not significantly altered after the CB → M1 PAS in this study. Whether the current CB → M1 protocols modulate GABA-ergic interneurons needs further clarification.

Neurological disorders can diminish or disrupt SICI \[for a review, see Berardelli et al. ([@B35])\]. Evidences have shown that patients with PD have a reduced SICI ([@B36]). Patients with SCA3 also presented a significant reduction of SICI compared to HCs ([@B37]). Our data on SICI are consistent with the previous findings and further suggest that patients with SCA3 may bear a more profound functional deficit on M1 inhibitory interneurons compared to patients with PD.

There was no remarkable ICF alteration through the CB → M1 PAS protocols. The finding is consistent with the previous report ([@B13]), supporting the notion that distinct mechanisms govern MEP vs. ICF modulation by CB → M1 PAS.

CBI Response {#S4-3}
------------

With the established paired-coil protocol ([@B8]), we found that the baseline CBI in the healthy elder subjects was less consistent than the young subjects \[84.7 ± 14.9% (Figure [3](#F3){ref-type="fig"}) vs. 78.4 ± 3.1% ([@B13])\]. CBI has been supposed to play an important role in selective tonic muscle movement, probably through a topographically specific reduction of inhibition in M1 ([@B38]). The fact that CBI showed a less consistence in the elder subjects might reflex a physiological feature of the aging process in humans.

Cerebellar inhibition was significantly reduced immediately and 60 min after the CB → M1 PAS irrespective of PAS protocol in the control group (Figure [3](#F3){ref-type="fig"}). It is noted that low-intensity rTMS can modify Purkinje cell dendrites and induce climbing fibers reinnervation ([@B39]). It is likely that 0.25 Hz rTMS with the current intensity (i.e., 95% individual inion AMT) actually induce inhibition on the Purkinje cells, which consequently resulted in the reduction of CBI. Nevertheless, CBI did not show any significant change throughout the CB → M1 PAS in the PD group and the SCA3 group. PD patients may bear some degree of functional perturbation in the CDTC pathway ([@B4], [@B14]). Therefore, it would be reasonable that CBI is not well responsive to the CB → M1 PAS which largely depends on a functionally intact CDTC circuit. In addition, CBI may be already impaired in patients with PD ([@B40]). The baseline CBI in the current PD group (91.9 ± 21.1%, Figure [3](#F3){ref-type="fig"}) was consistent with this notion. CBI was not found in our SCA3 group. The finding was compatible with the imaging evidence showing that patients with SCA3 have a significant reduction of the dentate volume and abnormal dentate activation ([@B5]).

There are limitations in this study. We only measured the effect of right CB → left M1 PAS. Since the dominant symptoms in our PD patients were not fixed at the same side (Table [1](#T1){ref-type="table"}), someone may concern that the inconsistence of the more affected side potentially influences the current finding because motor cortical plasticity induced by conventional PAS has been reported increased on the less affected side and decreased on the more affected side ([@B41]). In this study, there were six PD patients presented their more affected side on the left side and four on the right side. Therefore, we would overestimate rather than underestimate the PAS-induced M1 motor plasticity for the PD group. Another concern is the significant difference of the levodopa equivalent dose between the PD and SCA3 group. A higher levodopa equivalent dose was prescribed for the PD group than that for the SCA3 group. Levodopa has been found with a dose-dependent effect to the conventional PAS-induced M1 motor plasticity ([@B42]). Despite the fact that we have minimized the confounding factor by ceasing medications for at least 24 h, it can be still difficult to completely exclude the influence caused by the levodopa equivalent dose difference between the PD and the SCA3 group. Nevertheless, the fact that the PD group and the SCA3 group both showed impaired M1 motor plasticity suggests that the difference of the levodopa equivalent dose might be not a key factor influencing the current finding. In this study, the SCA3 group revealed a less mean age than the PD group. People with young age have been found with a more capacity to induce M1 motor plasticity than those with old age ([@B25]). Therefore, we would underestimate the impairment of the M1 plasticity for the SCA3 group. Finally, the application of the double cone coil for cerebellar stimulation also bears concerns. The large coil may excite sensory afferent fibers in the brachial plexus or the spinal dorsal nerve roots and antidromically excite the pyramidal tract at the foramen magnum level.

Conclusion {#S5}
==========

Corticocortical CB → M1 PAS induced bidirectional motor cortical plasticity in M1 for healthy aged subjects. The modulation relies on the STDP-like principle and seems to be independent of the inhibitory neurocircuits, such as SICI and CBI and the facilitatory mechanism like ICF. There was no such kind of plasticity in patients with PD and SCA3. Findings suggest that neurodegenerative diseases with pathology in the CDTC pathway and/or the CB may erase this type of plasticity. The CB → M1 PAS is supposed to be an alternative route for modulating M1 plasticity and a useful tool in evaluating the functional integrity of the CDTC pathway.
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